High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma

Leuk Lymphoma. 2010 Nov;51(11):2126-9. doi: 10.3109/10428194.2010.509893. Epub 2010 Sep 21.
No abstract available

Publication types

  • Evaluation Study
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Pharmacological / metabolism
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Male
  • Microarray Analysis
  • Middle Aged
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / mortality
  • Prognosis
  • Survival Analysis
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / genetics*
  • TOR Serine-Threonine Kinases / metabolism
  • Thalidomide / therapeutic use*
  • Up-Regulation

Substances

  • Antineoplastic Agents
  • Biomarkers, Pharmacological
  • Biomarkers, Tumor
  • Intracellular Signaling Peptides and Proteins
  • Thalidomide
  • DEPTOR protein, human
  • MTOR protein, human
  • TOR Serine-Threonine Kinases